COMBINED THERAPY FOR THYROID SQUAMOUS CELL CARCINOMA

Filip Vos; A. Sewnaik; JHW (Johannes) de Wilt; EJ (Ernst) Smid; Michael den Bakker; Esther van Meerten

doi:10.1002/hed.21484

COMBINED THERAPY FOR THYROID SQUAMOUS CELL CARCINOMA

Filip Vos, A. Sewnaik, JHW (Johannes) de Wilt, EJ (Ernst) Smid, Michael den Bakker, Esther van Meerten

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Abstract

Background. Squamous carcinoma of the thyroid is a rare aggressive disease, resulting in poor prognosis. Methods and Results. We combined cisplatin with paclitaxel on a weekly basis as induction therapy, achieving a high cumulative dose, in a patient with squamous cell tumor of the thyroid with arterial encasement. After surgery, pathologic examination confirmed a complete resection of the primary tumor with clear margins, revealing a successful induction treatment with chemotherapy. Conclusions. Our patient now has a recurrence-free survival of >20 months, longer than the mean survival described in the literature. (C) 2010 Wiley Periodicals, Inc. Head Neck 34: 131-134, 2012

Original language	Undefined/Unknown
Pages (from-to)	131-134
Number of pages	4
Journal	Head & Neck-Journal for the Sciences and Specialties of the Head and Neck
Volume	34
Issue number	1
DOIs	https://doi.org/10.1002/hed.21484
Publication status	Published - 2012

Access to Document

10.1002/hed.21484

http://hdl.handle.net/1765/34858

Cite this

@article{7821d7916350466bb24f224f7dac9f2b,

title = "COMBINED THERAPY FOR THYROID SQUAMOUS CELL CARCINOMA",

abstract = "Background. Squamous carcinoma of the thyroid is a rare aggressive disease, resulting in poor prognosis. Methods and Results. We combined cisplatin with paclitaxel on a weekly basis as induction therapy, achieving a high cumulative dose, in a patient with squamous cell tumor of the thyroid with arterial encasement. After surgery, pathologic examination confirmed a complete resection of the primary tumor with clear margins, revealing a successful induction treatment with chemotherapy. Conclusions. Our patient now has a recurrence-free survival of >20 months, longer than the mean survival described in the literature. (C) 2010 Wiley Periodicals, Inc. Head Neck 34: 131-134, 2012",

author = "Filip Vos and A. Sewnaik and {de Wilt}, {JHW (Johannes)} and Smid, {EJ (Ernst)} and {den Bakker}, Michael and {van Meerten}, Esther",

year = "2012",

doi = "10.1002/hed.21484",

language = "Undefined/Unknown",

volume = "34",

pages = "131--134",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley & Sons Inc.",

number = "1",

}

TY - JOUR

T1 - COMBINED THERAPY FOR THYROID SQUAMOUS CELL CARCINOMA

AU - Vos, Filip

AU - Sewnaik, A.

AU - de Wilt, JHW (Johannes)

AU - Smid, EJ (Ernst)

AU - den Bakker, Michael

AU - van Meerten, Esther

PY - 2012

Y1 - 2012

N2 - Background. Squamous carcinoma of the thyroid is a rare aggressive disease, resulting in poor prognosis. Methods and Results. We combined cisplatin with paclitaxel on a weekly basis as induction therapy, achieving a high cumulative dose, in a patient with squamous cell tumor of the thyroid with arterial encasement. After surgery, pathologic examination confirmed a complete resection of the primary tumor with clear margins, revealing a successful induction treatment with chemotherapy. Conclusions. Our patient now has a recurrence-free survival of >20 months, longer than the mean survival described in the literature. (C) 2010 Wiley Periodicals, Inc. Head Neck 34: 131-134, 2012

AB - Background. Squamous carcinoma of the thyroid is a rare aggressive disease, resulting in poor prognosis. Methods and Results. We combined cisplatin with paclitaxel on a weekly basis as induction therapy, achieving a high cumulative dose, in a patient with squamous cell tumor of the thyroid with arterial encasement. After surgery, pathologic examination confirmed a complete resection of the primary tumor with clear margins, revealing a successful induction treatment with chemotherapy. Conclusions. Our patient now has a recurrence-free survival of >20 months, longer than the mean survival described in the literature. (C) 2010 Wiley Periodicals, Inc. Head Neck 34: 131-134, 2012

U2 - 10.1002/hed.21484

DO - 10.1002/hed.21484

M3 - Article

VL - 34

SP - 131

EP - 134

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 1

ER -